Telomir Pharmaceuticals (TELO) and Its Peers Head-To-Head Survey

Telomir Pharmaceuticals (NASDAQ:TELO) is one of 1,069 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Telomir Pharmaceuticals to related businesses based on the strength of its profitability, risk, valuation, analyst recommendations, earnings, institutional ownership and dividends.

Profitability

This table compares Telomir Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-1,170.58%	-832.67%
Telomir Pharmaceuticals Competitors	-3,399.87%	-235.11%	-32.77%

Insider and Institutional Ownership

44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Telomir Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	-$16.53 million	-7.10
Telomir Pharmaceuticals Competitors	$9.93 billion	$136.87 million	-7.53

Telomir Pharmaceuticals’ rivals have higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current recommendations for Telomir Pharmaceuticals and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	0	0	1	1	3.50
Telomir Pharmaceuticals Competitors	8345	22150	50252	1343	2.54

Telomir Pharmaceuticals currently has a consensus target price of $15.00, suggesting a potential upside of 264.08%. As a group, “Pharmaceutical preparations” companies have a potential upside of 212.51%. Given Telomir Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Telomir Pharmaceuticals is more favorable than its rivals.

Summary

Telomir Pharmaceuticals rivals beat Telomir Pharmaceuticals on 7 of the 12 factors compared.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.